Brief: BrainsWay Says Centene Published Positive Coverage Policy For Treatment Of OCD Using BrainsWay Deep TMS System
24/05/2021 13:27
May 24 (Reuters) - Brainsway Ltd BWAY.TA :
* BRAINSWAY - CENTENE CORP PUBLISHED POSITIVE COVERAGE
POLICY FOR
DEEP TRANSCRANIAL MAGNETIC STIMULATION TREATMENT OF OCD USING
BRAINSWAY DEEP TMS SYSTEM
Source text for Eikon: ID:nGNX94xq34
Further company coverage: BWAY.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainsway
See all newsBrief: Brainsway Presents Positive Data From Largest Real-World Study Of Deep Tms™ In Patients With Comorbid Ptsd And Major Depressive Disorder
Brief: Brainsway Announces Minority-Stake Investment In Hopemark Health
Brief: Brainsway Announces New Minority-Stake Investment In Canadian Provider, Brainstim Health Inc.
Brief: Brainsway Announces Change In ADS-To-Ordinary Share Ratio
Brief: BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)